Skip to content
Screener

Beta Bionics BBNX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Insulet logo
InsuletPODD
$3.17B-8.8%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$1.15B+31.8%
Medtronic logo
MedtronicMDT
$93.03B+1.5%
Embecta Corp. logo
Embecta Corp.EMBC
$1.27B+9.3%
AdaptHealth logo
AdaptHealthAHCO
$4.42B-0.3%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$2.58B+25.5%

Other financials

Income statement

See full
Revenue$32.0M+37.8%
Gross profit$18.9M+51.2%
Operating income-$25.6M-28.7%
Net income-$23.4M-38.7%
EPS (diluted)-$0.53-35.9%

Balance sheet

See full
Cash & equivalents$44.3M+26.4%
Total debt$6.5M-2.6%
Total equity$256.4M-15.0%
Total assets$292.4M-11.4%

Cash flow

See full
Operating cash flow-$14.6M-7.6%
CapEx$1.0M-41.6%
Free cash flow-$15.7M-1.9%

Valuation

See full
Market cap$715.34M+15.1%
Enterprise value$677.53M+14.2%
P/S-2.0×

Profitability

See full
Gross margin58.3%+4.4pp
Operating margin-69.8%-8.0pp
Net margin-61.3%-15.8pp
FCF margin-51.6%-13.4pp

Returns & leverage

See full
Return on equity-26.2%
Debt / equity0.0×
Current ratio8.9×-5.8×

Where this comes from

Reported directly by Beta Bionics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323777
Line itemJune 30,2026December 31,2025
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, $0.0001 par value, 700,000,000 shares authorized; 44,981,606 and 44,360,873 issued and outstanding at June 30, 2026 and December 31, 2025, respectively54
Additional paid-in capital671,986657,140
Accumulated other comprehensive income (loss)(390)403
Accumulated deficit(415,235)(369,937)
Total stockholders’ equity256,366287,610
Total liabilities and stockholders’ equity$292,387$328,743

Item 1. Financial Statements.

FAQ

What is Beta Bionics's total liabilities & equity?
Beta Bionics (BBNX) reported total liabilities & equity of $292.39M in Q2 2026.
How has Beta Bionics's total liabilities & equity changed year-over-year?
Beta Bionics's total liabilities & equity decreased by 11.4% year-over-year, from $329.97M to $292.39M.
What is the long-term trend for Beta Bionics's total liabilities & equity?
Over 2 years (2023 to 2025), Beta Bionics's total liabilities & equity has grown at a 72.8% compound annual growth rate (CAGR), from $110.04M to $328.74M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Beta Bionics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude